Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MT110 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| I | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MT110 | BIOLOGICAL | MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses |
Inclusion Criteria: 1. Locally advanced, recurrent or metastatic solid tumors known to widely express EpCAM and proven histology of the following entities: * Adenocarcinoma of the lung * Small cell lung cancer (SCLC) * Gastric cancer or adenocarcinoma of gastro-esophageal junction * Co...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MT110 is an investigational monoclonal antibody being developed for the treatment of solid tumors, including lung cancer (adenocarcinoma and small cell), gastric cancer, adenocarcinoma of the gastro-esophageal junction, colorectal cancer, breast cancer, hormone-refractory prostate cancer, and ovarian cancer. It is currently in Phase 1 clinical development.
MT110 is being developed by Amgen Inc. (NASDAQ: AMGN). The company is conducting clinical trials to evaluate the safety and efficacy of this investigational monoclonal antibody in patients with solid tumors.
MT110 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study of MT110 has been completed, involving 65 patients with various types of solid tumors.
MT110 has been studied in one clinical trial, registered as NCT00635596. This was a Phase 1 study conducted in Germany that enrolled 65 patients with solid tumors, including lung, gastric, colorectal, breast, prostate, and ovarian cancers. The trial has been completed.
MT110 is the primary name for this investigational monoclonal antibody. No alternative names have been disclosed in the available clinical trial information. It is being studied under this name in the completed Phase 1 trial.